A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (purified poloxamer 188) Injection in Children with Sickle Cell Disease Experiencing Vaso-occlusive Crisis

This is a randomized study, where each patient will be assigned to receive either MST-188 (the study drug) or a placebo. The study drug or placebo will be administered intravenously, directly into the vein, for up to 49 hours (about 2 days). About 388 children with sickle cell disease in vaso-occlusive pain crisis will be enrolled in this research study from 70 centers in the Americas, Europe, and the Middle East.